EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Hinta Meijerink

Work experience

1. Employer: Radboud University Medical Center
   - Start date: 082009
   - End date: 082010
   - Position: Scientific Reseacher
   - Activities:
   - Country: Netherlands
2. Employer: Radboud University Medical Center
   - Start date: 082010
   - End date: 082014
   - Position: Scientific Researcher _ PhD student
   - Activities: HIV among injecting drug users
   - Country: Netherlands
3. Employer: Norwegian Institute of Public Health
   - Start date: 092014
   - End date: 092014
   - Position: Advisor
   - Activities:
   - Country: Norway
4. Employer: Coalition for Epidemic Preparedness Innovations
   - Start date: 092015
   - End date: 012019
   - Position: Senior scientist
   - Activities:
   - Country: Norway
5. Employer: Norwegian Institute of Public Health
   - Start date: 012020
   - End date:
   - Position: Senior Advisor
   - Activities:
   - Country: Norway

Education and training

1. Subject:
   - Start date: 092014
   - End date: 092016
   - Qualification: EPIET _ European Programme for Intervention Epidemiology Training
   - Organisation:
   - Country:
2. Subject:
   - Start date: 082010
   - End date: 092014
   - Qualification: PhD in epidemiology
   - Organisation:
   - Country:
3. Subject:
   - Start date:
   - End date:
   - Qualification: Master in Epidemiology
   - Organisation:
   - Country:

Additional information

Publications

1. Starrfelt J, Danielsen AS, Kacelnik O, Wang Børseth A, Seppälä E, Meijerink H. High vaccine effectiveness against coronavirus disease 2019 (COVID_19) and severe disease among residents and staff of long_term care facilities in Norway, November 2020_June 2021. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e10. 2. Starrfelt J, Danielsen AS, Buanes EA, Juvet LK, Lyngstad TM, Rø G, et al. Age and product dependent vaccine effectiveness against SARS_CoV_2 infection and hospitalisation among adults in Norway: a national cohort study, July_November 2021. BMC Med. 2022;20(1):278. 3. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez_Baz I, et al. Estimation of COVID_19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. Euro Surveill. 2022;27(30). 4. Jalali N, Brustad HK, Frigessi A, MacDonald EA, Meijerink H, Feruglio SL, et al. Increased household transmission and immune escape of the SARS_CoV_2 Omicron compared to Delta variants. Nat Commun. 2022;13(1):5706. 5. Winje BA, Ofitserova TS, Brynildsrud OB, Greve_Isdahl M, Bragstad K, Rykkvin R, et al. Comprehensive Contact Tracing, Testing and Sequencing Show Limited Transmission of SARS_CoV_2 between Children in Schools in Norway, August 2020 to May 2021. Microorganisms. 2021;9(12). 6. Seppälä E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O, et al. Vaccine effectiveness against

infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. Euro Surveill. 2021;26(35). 7. Meslé MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID_19 vaccination in the WHO European Region, December 2020 to November 2021. Euro Surveill. 2021;26(47). 8. Meijerink H, Mauroy C, Johansen MK, Braaten SM, Lunde CUS, Arnesen TM, et al. The First GAEN_Based COVID_19 Contact Tracing App in Norway Identifies 80% of Close Contacts in "Real Life" Scenarios. Front Digit Health. 2021;3:731098. 9. Brandal LT, Ofitserova TS, Meijerink H, Rykkvin R, Lund HM, Hungnes O, et al. Minimal transmission of SARS_CoV_2 from paediatric COVID_19 cases in primary schools, Norway, August to November 2020. Euro Surveill. 2021;26(1). 10. Franer K, Meijerink H, Hyllestad S. Compliance with a boil water advisory after the contamination of a municipal drinking water supply system in Norway. J Water Health. 2020;18(6):1084_90. 11. Wisløff T, White R, Dalgard O, Amundsen EJ, Meijerink H, Løvlie AL, et al. Economic Evaluation of Direct_Acting Antivirals for Hepatitis C in Norway. Pharmacoeconomics. 2018;36(5):591_601. 12. Wisløff T, White R, Dalgard O, Amundsen EJ, Meijerink H, Kløvstad H. Feasibility of reaching world health organization targets for hepatitis C and the cost_effectiveness of alternative strategies. J Viral Hepat. 2018;25(9):1066_77. 13. Meijerink H, White RA, Løvlie A, de Blasio BF, Dalgard O, Amundsen EJ, et al. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973_2030. BMC Infect Dis. 2017;17(1):541. 14. Meijerink H, Lamagni T, Eriksen HM, Elgohari S, Harrington P, Kacelnik O. Is It Valid to Compare Surgical Site Infections Rates Between Countries? Insights From a Study of English and Norwegian Surveillance Systems. Infect Control Hosp Epidemiol. 2017;38(2):162_71. 15. Rahmalia A, Wisaksana R, Meijerink H, Indrati AR, Alisjahbana B, Roeleveld N, et al. Women with HIV in Indonesia: are they bridging a concentrated epidemic to the wider community? BMC Res Notes. 2015;8:757. 16. Meijerink H, Wisaksana R, Lestari M, Meilana I, Chaidir L, van der Ven AJ, et al. Active and latent tuberculosis among HIV_positive injecting drug users in Indonesia. J Int AIDS Soc. 2015;18(1):19317. 17. Meijerink H, Indrati AR, Soedarmo S, Utami F, de Jong CA, Alisjahbana B, et al. Heroin use in Indonesia is associated with higher expression of CCR5 on CD4+ cells and lower ex_vivo production of CCR5 ligands. Aids. 2015;29(3):385_8. 18. Meijerink H, Indrati A, Utami F, Soedarmo S, Alisjahbana B, Netea MG, et al. Heroin use is associated with suppressed pro_inflammatory cytokine response after LPS exposure in HIV_infected individuals. PLoS One. 2015;10(4):e0122822. 19. Meijerink H, Wisaksana R, Iskandar S, den Heijer M, van der Ven AJ, Alisjahbana B, et al. Injecting drug use is associated with a more rapid CD4 cell decline among treatment naïve HIV_positive patients in Indonesia. J Int AIDS Soc. 2014;17(1):18844. 20. Meijerink H, Tacke S, Indrati A, Wisaksana R, Alisjahbana B, van der Ven A. Decreased whole blood RNA expression of cathelicidin in HIV_infected heroin users in Bandung, Indonesia. Viral Immunol. 2014;27(10):551_5. 21. Meijerink H, Indrati AR, van Crevel R, Joosten I, Koenen H, van der Ven AJ. The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV_infected long_term non_progressors with viral control compared to normal progressors: a cross_sectional study. BMC Infect Dis. 2014;14:683. 22. Haverkate M, Smits J, Meijerink H, van der Ven A. Socioeconomic determinants of haemoglobin levels of African women are less important in areas with more health facilities: a multilevel analysis. J Epidemiol Community Health. 2014;68(2):116_22. 23. Ganiem AR, Indrati AR, Wisaksana R, Meijerink H, van der Ven A, Alisjahbana B, et al. Asymptomatic cryptococcal antigenemia is associated with mortality among HIV_positive patients in Indonesia. J Int AIDS Soc. 2014;17(1):18821. 24. Meijerink H, van Crevel R, van der Ven AJ. [Intravenous drug use and the spread of HIV; an international perspective]. Ned Tijdschr Geneeskd. 2013;157(21):A5690. 25. de Jong MA, Wisaksana R, Meijerink H, Indrati A, van de Ven AJ, Alisjahbana B, et al. Total lymphocyte count is a reliable surrogate marker for CD4 cell counts after the first year of antiretroviral therapy: data from an Indonesian cohort study. Trop Med Int Health. 2012;17(5):581_3. 26. Oudenhoven HP, Meijerink H, Wisaksana R, Oetojo S, Indrati A, van der Ven AJ, et al. Total lymphocyte count is a good marker for HIV_related mortality and can be used as a tool for starting HIV treatment in a resource_limited setting. Trop Med Int Health. 2011;16(11):1372_9. 27. Bousema T, Roeffen W, Meijerink H, Mwerinde H, Mwakalinga S, van Gemert GJ, et al. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS One. 2010;5(11):e14114.

Projects

EMA funded project regarding vaccine effectiveness: EMA/2020/46/TDA/L5.04 (DKMA), Study report: https://www.encepp.eu/encepp/openAttachment/studyResult/48760 and https://www.encepp.eu/encepp/openAttachment/documents.otherDocument_0/48761 VERBIS4 _ development and use of standardized protocol to estimate vaccine effectiveness using registry data in Europe Global Preparedness Monitoring Board (GPMB): background document for the annual report in 2020: Urbanization and preparedness for outbreaks with high_impact respiratory pathogens https://www.gpmb.org/annual_reports/overview/item/urbanization_and_preparedness_for_outbreaks_with_high_impact_respiratory_pathogens

Memberships

Other Relevant Information